# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ardelyx's analysis of the CMS policy to include oral-only medicines in the PPS and the Calendar Year 2025 ESRD PPS Proposed...
Cantor Fitzgerald analyst Louise Chen reiterates Ardelyx (NASDAQ:ARDX) with a Overweight.
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and maintains $15 price target.
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $15 price target.